Knome Selected as a Genome Interpretation Partner for Illumina, Inc. (ILMN) Genome Network
4/3/2012 10:15:52 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Knome Inc., the human genome interpretation company, announced today that it has been selected by Illumina, Inc., (NASDAQ: ILMN) as a partner in the Illumina Genome Network (IGN). As part of the agreement, IGN customers will have access to preferential pricing for Knome’s genome interpretation tools and services. The agreement also calls for the companies to further integrate their data pipelines in order to provide end users with accelerated turnaround times.